US › Healthcare

Lucid Diagnostics Inc (LUCD)

US · Healthcare · Medical Devices

$0.96-0.95%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.3M
Revenue YoY
+51.7%
Net profit
$-13.9M
Profit YoY
+48.3%
EPS
$-0.07
EPS estimate
$-0.06
Net margin
-1,107.4%

EPS came in at -0.07 against a street estimate of -0.06 — a miss of 16.7%.

Key statistics

Market cap
$166.3M
Forward P/E
0.0
P/B
2.16
Book value
$-0.04
EPS (TTM)
$-0.34
52-week high
$1.63
52-week low
$0.86
50-day MA
$1.00
200-day MA
$1.14
Beta
1.07

Analyst view

Analysts rate Lucid Diagnostics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $3.95.

Shareholding

Insiders
26.53%
Institutions
19.65%

Largest institutional holders

FundStake
BlackRock Inc2.43%
Vanguard Capital Management, LLC2.18%
Masters Capital Management LLC2.10%
Aberdeen Group PLC1.91%
Two Seas Capital LP1.57%
Geode Capital Management, LLC1.18%
State Street Corp0.81%
Wells Fargo & Co0.67%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lucid Diagnostics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.